About Us

Exoxemis is a biomedical research company focused on the study and commercialization of Zempia®, our trade name for a topical biological antiseptic system utilizing Myeloperoxidase (MPO). Exoxemis develops haloperoxidase products for prevention and treatment of serious infections.

Our Team

Exoxemis is a privately held company that draws from academia, private industry, and government to maximize competitiveness, innovation, and intellectual capital. Our scientific team spans a wide range of research and clinical expertise with strong collective credentials in fundamental research, product development, pre-clinical, and clinical development. This combined expertise, experience, and demonstrated commitment to both internal R&D and partnership success enables Exoxemis to bring new and innovative products to the market.

Manufacturing

Exoxemis supplies pharmaceutical-grade haloperoxidase enzymes. Manufacturing processes have been successfully demonstrated and our robust, scalable protein purification process is documented under cGMP requirements. Exoxemis will design and test MPO formulations to produce a steady stream of new products and seeks to commercialize products with partners who complement our capabilities.